Tag: crpc or hrpca therapeutics market

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth Potential: How Will Market Size Shift Through 2030?#_x000D_

The market for therapeutics addressing castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) has shown significant growth in recent years. It is forecast to increase from $8.43 billion in 2025 to $8.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. Historically, this expansion has been influenced by factors such as the widespread occurrence of prostate cancer, the emergence of resistance to hormone therapy, breakthroughs in oncology drug development, the provision of hospital-based cancer treatment, and the growing demographic of aging males._x000D_

_x000D_

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size is projected to demonstrate significant growth over the next few years. It is expected to reach $11.04 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. The expansion foreseen during the forecast period can be attributed to factors such as biomarker-driven treatment, advanced targeted therapies, the adoption of oral oncology, the expansion of the oncology pipeline, and personalized cancer care. Significant trends anticipated in this period involve the increasing utilization of androgen receptor inhibitors, the development of PARP inhibitor therapies, the broadening of combination treatment regimens, a greater emphasis on precision oncology, and a shift towards oral oncology drugs._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=80658895&type=smp&name=Castration-Resistant%20Prostate%20Cancer%20%28CRPC%29%20Or%20Hormone-Refractory%20Prostate%20Cancer%20%28HRPCA%29%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Industry Drivers: What’s Behind The Revenue Growth?#_x000D_

The increasing incidence of prostate cancer is projected to propel the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the coming years. Prostate cancer is defined as a malignant condition that develops within the prostate gland, a small organ found in men, positioned below the bladder and anterior to the rectum. This growing prevalence of prostate cancer is primarily attributed to the aging demographic, given that the risk of developing the disease significantly increases with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are instrumental in treating prostate cancer by targeting its advanced stages that no longer respond to conventional hormone therapy. These treatments enhance patient outcomes by slowing disease progression and managing associated symptoms, thereby improving their quality of life. As an illustration, in October 2025, NHS Digital, a UK-based government agency responsible for healthcare data and statistics, reported 58,137 new diagnoses of prostate cancer in England in 2023, which represented a 6 percent increase compared with 2022. Thus, the rising occurrence of prostate cancer is fundamentally driving the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market._x000D_

_x000D_

#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmentation: How Does The Market Break Down By Category?#_x000D_

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented – _x000D_

_x000D_

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy_x000D_

2) By Route Of Administration: Oral, Injectable, Intravenous_x000D_

3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists_x000D_

2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies_x000D_

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines_x000D_

4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors_x000D_

5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals_x000D_

_x000D_

#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth Trends: What’s Shaping The Future Outlook?_x000D_

Within the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market, leading companies are concentrating on developing novel products and securing approvals, such as for dual-action tablets, to enhance treatment efficacy and patient outcomes. Dual-action tablets represent advanced formulations that combine two therapeutic agents in a single dose to simultaneously target multiple pathways in castration-resistant prostate cancer (CRPC) treatment. Illustratively, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Akeega, a new tablet created for adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that integrates a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically aimed at patients with BRCA mutations. When administered alongside prednisone, it markedly improves radiographic progression-free survival (rPFS) in comparison to conventional hormonal therapy alone._x000D_

_x000D_

#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Competitive Overview And Top Companies#_x000D_

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc. _x000D_

_x000D_

#View The Full Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Geographic Analysis: Where Is Demand Accelerating Fastest?#_x000D_

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Expansion From $8.92 Billion In 2026 To $11.04 Billion In 2030

In recent years, the market for castration-resistant prostate cancer (CRPC) and hormone-refractory prostate cancer (HRPCA) therapeutics has experienced substantial expansion. Projections indicate it will rise from $8.43 billion in 2025 to $8.92 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This historic growth is driven by factors such as the high prevalence of prostate cancer, the development of resistance to hormone therapies, progress in oncology drug innovation, the provision of cancer care within hospital settings, and an increasing demographic of older men.

The market size for therapeutics targeting castration-resistant prostate cancer, also referred to as hormone-refractory prostate cancer, is projected to experience considerable expansion over the coming years. By 2030, this market is anticipated to reach $11.04 billion, reflecting a compound annual growth rate of 5.5%. This predicted growth during the forecast period is driven by factors such as the increasing reliance on biomarker-driven treatment strategies, the development of more advanced targeted therapies, a growing shift toward oral oncology medications, an expanding pipeline of oncology drugs, and a stronger emphasis on personalized cancer care. Key trends shaping the market in this period include the growing utilization of androgen receptor inhibitors, the expansion of PARP inhibitor therapies, the rising number of combination treatment protocols, a heightened focus on precision oncology, and a steady transition toward adopting oral oncology drugs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Opportunity Drivers: What Is Creating New Revenue Potential?

The increasing incidence of prostate cancer is expected to drive the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the coming years. Prostate cancer is defined as a malignancy that develops in the prostate gland, a small male reproductive organ positioned beneath the bladder and in front of the rectum. This rise in prostate cancer cases is largely attributed to an aging population, given that the likelihood of developing this condition significantly escalates with advancing age. Therapeutics designed for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) are utilized to manage the disease by focusing on its advanced phases, where it no longer reacts to standard hormone-based treatments. These therapies enhance patient outcomes by decelerating disease advancement and alleviating symptoms, which ultimately improves the quality of life. To illustrate, in October 2025, NHS Digital—a UK-based government body overseeing healthcare statistics—reported that England recorded 58,137 new prostate cancer cases in 2023, indicating a 6 percent rise from the previous year. Consequently, the growing prevalence of prostate cancer is fueling the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segment Breakdown: Which Categories Generate The Most Revenue?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectable, Intravenous

3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists

2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors

5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Innovation Trends Driving Future Development

Key players in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutic market are prioritizing the development of innovative products, including dual-action tablets, to improve treatment effectiveness and patient outcomes. These dual-action tablets are advanced formulations delivering two therapeutic agents in a single dose, designed to simultaneously target multiple pathways in the treatment of CRPC. A notable example occurred in August 2023, when Janssen Pharmaceuticals, a Belgium-based firm, secured U.S. Food and Drug Administration (FDA) approval for Akeega, a novel tablet intended for adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). This precision medicine integrates a PARP inhibitor (niraparib) and a CYP17 inhibitor (abiraterone acetate), specifically tailored for patients with BRCA mutations. When administered with prednisone, it markedly extends radiographic progression-free survival (rPFS) relative to standard hormonal therapy.

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Key Players And Strategic Industry Positioning

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Access The Complete Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market During The 2026–2030 Period?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size has seen strong growth in recent years. It is forecast to increase from $8.43 billion in 2025 to $8.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. Historically, this growth has been driven by factors such as the prevalence of prostate cancer, resistance to hormone therapy, advancements in oncology drug innovation, the availability of hospital-based cancer care, and the demographic shift towards an aging male population.

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market is set to experience significant expansion over the next few years. It is forecast to increase to $11.04 billion in 2030, achieving a compound annual growth rate (CAGR) of 5.5%. This projected growth is driven by advancements such as biomarker-driven treatment, sophisticated targeted therapies, the uptake of oral oncology solutions, an expanding oncology pipeline, and individualized cancer care. Notable trends anticipated during this period encompass the increasing deployment of androgen receptor inhibitors, the rise of PARP inhibitor therapies, the broadening of combination treatment regimens, a greater emphasis on precision oncology, and a move towards oral oncology medications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp

Which Strategic Drivers Are Supporting The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Development?

The increasing occurrence of prostate cancer is projected to fuel the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market moving ahead. Prostate cancer is defined as a malignancy that forms within the prostate gland, which is a small male gland situated beneath the bladder and anterior to the rectum. The growing incidence of prostate cancer stems from an aging demographic, given that the likelihood of developing this cancer substantially increases with advancing age. Therapies for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) are instrumental in managing prostate cancer by addressing later stages of the illness that have become unresponsive to standard hormone treatment. These treatments improve patient results by decelerating the progression of the disease and alleviating symptoms, consequently improving the overall quality of life. As an illustration, in October 2025, data from NHS Digital, a UK-based government agency focused on healthcare statistics, indicated 58,137 new prostate cancer diagnoses in England during 2023, marking a 6 percent rise from 2022. Consequently, the escalating prevalence of prostate cancer is stimulating the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.

How Does Segment Analysis Break Down The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Structure?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectable, Intravenous

3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists

2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors

5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

What Trends Are Influencing The Future Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Leading companies in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are concentrating on developing innovative products and securing approvals, such as dual-action tablets, to enhance treatment efficacy and patient outcomes. Dual-action tablets represent advanced formulations that combine two therapeutic agents in a single dose to simultaneously target multiple pathways in castration-resistant prostate cancer (CRPC) treatment. For instance, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Akeega, a novel tablet developed for the treatment of adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that combines a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically targeting patients with BRCA mutations. When used alongside prednisone, it significantly enhances radiographic progression-free survival (rPFS) compared to conventional hormonal therapy alone.

Which Companies Are Engaged In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Environment?

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Access The Complete Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report

Which Area Represents The Largest Portion Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp

Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Urothelial Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Grow Between 2026 And 2030?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market has experienced significant expansion in recent years. This market is anticipated to increase from $8.43 billion in 2025 to $8.92 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. Factors such as prostate cancer prevalence, hormone therapy resistance, oncology drug innovation, hospital-based cancer care, and the aging male population are credited with its past growth.

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market is set to experience substantial growth in the upcoming years. It is projected to expand to $11.04 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. The expansion anticipated during this period can be ascribed to several factors, including biomarker-driven treatment approaches, advanced targeted therapies, the adoption of oral oncology, the widening oncology pipeline, and personalized cancer care. Furthermore, significant developments expected in the forecast period involve a rising utilization of androgen receptor inhibitors, the proliferation of PARP inhibitor therapies, an increase in combination treatment regimens, a greater emphasis on precision oncology, and a shift towards oral oncology drugs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp

Which Important Drivers Are Guiding The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth?

The increasing occurrence of prostate cancer is projected to drive the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the future. Prostate cancer is defined as a malignancy that forms within the prostate gland, which is a small male gland situated beneath the bladder and anterior to the rectum. This growth in prostate cancer cases is linked to an aging demographic, given that the likelihood of developing the condition rises considerably with advancing age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are instrumental in addressing prostate cancer by focusing on late-stage forms of the illness that have become unresponsive to standard hormone treatments. These therapies enhance patient results through decelerating disease advancement and alleviating symptoms, consequently improving the quality of life. As an illustration, in October 2025, data from NHS Digital, a UK-based government agency tasked with healthcare data and statistics, indicated 58,137 new prostate cancer diagnoses in England during 2023, which signifies a 6 percent rise from 2022. Consequently, the expanding incidence of prostate cancer is propelling the market growth for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics.

How Is The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Categorized Across Its Segment Groups?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectable, Intravenous

3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists

2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors

5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

What Trends Are Influencing The Evolution Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Companies operating primarily within the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are prioritizing the creation of innovative products and securing authorizations, such as dual-action tablets, to boost therapeutic effectiveness and patient results. Dual-action tablets are defined as sophisticated formulations that integrate two medicinal compounds in a single dose to concurrently address various mechanisms in castration-resistant prostate cancer (CRPC) treatment. For example, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, obtained authorization from the U.S. Food and Drug Administration (FDA) for Akeega, an innovative medication intended for managing adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega functions as a targeted therapy that unites a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), designed specifically for individuals presenting BRCA mutations. Administered in conjunction with prednisone, it markedly improves radiographic progression-free survival (rPFS) in contrast to sole conventional hormonal treatment.

Which Firms Are Influencing Competition In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Get The Full Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report

Which Region Is The Largest In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Urothelial Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Over The 2026–2030 Period?

The market size for castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics has demonstrated significant expansion in recent years. It is anticipated to increase from $8.43 billion in 2025 to $8.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to several factors, including the prevalence of prostate cancer, the emergence of hormone therapy resistance, continuous innovation in oncology drugs, the availability of hospital-based cancer care, and the rising aging male population.

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size is projected to experience robust expansion over the coming years. This market is set to reach a valuation of $11.04 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this anticipated growth during the forecast period include the rise of biomarker-driven treatment approaches, the development of advanced targeted therapies, increasing adoption of oral oncology drugs, expansion of the oncology drug pipeline, and a greater emphasis on personalized cancer care. Key trends expected during the same period encompass the growing utilization of androgen receptor inhibitors, the expansion of PARP inhibitor therapies, the broader application of combination treatment regimens, a heightened focus on precision oncology, and a general move towards oral oncology medications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp

Which Economic Or Industry Drivers Are Impacting The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

The increasing occurrence of prostate cancer is anticipated to propel the future expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. Prostate cancer is a type of malignancy that develops in the prostate gland, a small male gland situated beneath the bladder and in front of the rectum. This rising prevalence is attributed to the aging population, as the likelihood of developing prostate cancer substantially increases with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are vital for treating prostate cancer by targeting advanced stages of the disease that no longer respond to conventional hormone therapy. These treatments enhance patient outcomes by slowing disease progression and managing symptoms, thereby improving the quality of life. For example, in October 2025, NHS Digital, a UK-based government agency responsible for healthcare data and statistics, reported 58,137 new diagnoses of prostate cancer in England in 2023, which signifies a 6 percent increase compared with 2022. Hence, the growing prevalence of prostate cancer is actively driving the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.

How Is The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmented Across Key Categories?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectable, Intravenous

3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists

2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors

5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

Which Upcoming Trends Are Expected To Influence The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Leading companies operating within the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are prioritizing the creation of novel products and obtaining necessary approvals, particularly for innovations like dual-action tablets, aimed at boosting treatment effectiveness and improving patient results. Dual-action tablets represent sophisticated formulations that integrate two therapeutic agents into a single dosage, allowing for the simultaneous targeting of multiple pathways crucial in castration-resistant prostate cancer (CRPC) treatment. A notable illustration occurred in August 2023, when Janssen Pharmaceuticals, a pharmaceutical company based in Belgium, secured approval from the U.S. Food and Drug Administration (FDA) for Akeega. This novel tablet is designed for treating adults diagnosed with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega functions as a precision medicine, bringing together a PARP inhibitor (niraparib) and a CYP17 inhibitor (abiraterone acetate), specifically tailored for patients carrying BRCA mutations. When administered alongside prednisone, it substantially improves radiographic progression-free survival (rPFS) when compared to conventional hormonal therapy on its own.

Who Are The Dominant Players Shaping The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Landscape?

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Read the full castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report

What Are The Top-Performing Regions Within The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24495&type=smp

Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Urothelial Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Over The 2026–2030 Period?

The market size for castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics has demonstrated significant expansion in recent years. It is anticipated to increase from $8.43 billion in 2025 to $8.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to several factors, including the prevalence of prostate cancer, the emergence of hormone therapy resistance, continuous innovation in oncology drugs, the availability of hospital-based cancer care, and the rising aging male population.

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size is projected to experience robust expansion over the coming years. This market is set to reach a valuation of $11.04 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this anticipated growth during the forecast period include the rise of biomarker-driven treatment approaches, the development of advanced targeted therapies, increasing adoption of oral oncology drugs, expansion of the oncology drug pipeline, and a greater emphasis on personalized cancer care. Key trends expected during the same period encompass the growing utilization of androgen receptor inhibitors, the expansion of PARP inhibitor therapies, the broader application of combination treatment regimens, a heightened focus on precision oncology, and a general move towards oral oncology medications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp

Which Economic Or Industry Drivers Are Impacting The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

The increasing occurrence of prostate cancer is anticipated to propel the future expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. Prostate cancer is a type of malignancy that develops in the prostate gland, a small male gland situated beneath the bladder and in front of the rectum. This rising prevalence is attributed to the aging population, as the likelihood of developing prostate cancer substantially increases with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are vital for treating prostate cancer by targeting advanced stages of the disease that no longer respond to conventional hormone therapy. These treatments enhance patient outcomes by slowing disease progression and managing symptoms, thereby improving the quality of life. For example, in October 2025, NHS Digital, a UK-based government agency responsible for healthcare data and statistics, reported 58,137 new diagnoses of prostate cancer in England in 2023, which signifies a 6 percent increase compared with 2022. Hence, the growing prevalence of prostate cancer is actively driving the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.

How Is The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmented Across Key Categories?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectable, Intravenous

3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists

2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors

5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

Which Upcoming Trends Are Expected To Influence The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Leading companies operating within the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are prioritizing the creation of novel products and obtaining necessary approvals, particularly for innovations like dual-action tablets, aimed at boosting treatment effectiveness and improving patient results. Dual-action tablets represent sophisticated formulations that integrate two therapeutic agents into a single dosage, allowing for the simultaneous targeting of multiple pathways crucial in castration-resistant prostate cancer (CRPC) treatment. A notable illustration occurred in August 2023, when Janssen Pharmaceuticals, a pharmaceutical company based in Belgium, secured approval from the U.S. Food and Drug Administration (FDA) for Akeega. This novel tablet is designed for treating adults diagnosed with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega functions as a precision medicine, bringing together a PARP inhibitor (niraparib) and a CYP17 inhibitor (abiraterone acetate), specifically tailored for patients carrying BRCA mutations. When administered alongside prednisone, it substantially improves radiographic progression-free survival (rPFS) when compared to conventional hormonal therapy on its own.

Who Are The Dominant Players Shaping The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Landscape?

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Read the full castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report

What Are The Top-Performing Regions Within The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24495&type=smp

Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Urothelial Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market from 2026–2035 with trusted insights from The Business Research Company

How is the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market size predicted to change over the forecast window of 2026–2035?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size has demonstrated robust growth in recent years. This market is projected to expand from $8.43 billion in 2025 to $8.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. The historical expansion of this market can be ascribed to several factors, including the prevalence of prostate cancer, the development of hormone therapy resistance, continuous innovation in oncology drugs, the provision of hospital-based cancer care, and an increasing aging male population.

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market is anticipated to experience robust expansion in the upcoming years. This market is projected to reach $11.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. The observed growth during the forecast period can be primarily attributed to factors such as biomarker-guided treatment approaches, cutting-edge targeted therapies, the increasing embrace of oral oncology, an expanding oncology drug pipeline, and the rise of personalized cancer care. Key trends expected over the forecast period encompass the escalating utilization of androgen receptor inhibitors, the proliferation of PARP inhibitor therapies, the broadening of combination treatment regimens, a heightened emphasis on precision oncology, and a general move towards oral oncology medications.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp

Which Drivers Are Contributing To The Expansion Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

The increasing occurrence of prostate cancer is anticipated to fuel the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. Prostate cancer is defined as a malignancy that forms within the prostate gland, a minor gland in males situated beneath the bladder and anterior to the rectum. This rise in prostate cancer cases is linked to an aging population, given that the likelihood of developing the condition grows considerably with advancing age. Therapies for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) aid in managing prostate cancer by addressing advanced disease stages that no longer respond to standard hormone treatment. These treatments enhance patient results by decelerating the disease’s progression and alleviating symptoms, thus improving their quality of life. As an example, in October 2025, data from NHS Digital, a UK government body overseeing healthcare statistics, showed 58,137 new prostate cancer diagnoses in England during 2023, marking a 6 percent rise from 2022. Consequently, the increasing prevalence of prostate cancer is propelling the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.

What Segment Classifications Make Up The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectable, Intravenous

3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists

2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors

5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

Which Trends Are Guiding The Evolution Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Major companies operating in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are concentrating on developing innovative products and securing approvals, such as dual-action tablets, to improve treatment efficacy and patient outcomes. Dual-action tablets are defined as advanced formulations that combine two therapeutic agents in a single dose to concurrently target multiple pathways in castration-resistant prostate cancer (CRPC) treatment. For example, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Akeega, a novel tablet designed for the treatment of adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that integrates a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically targeting patients with BRCA mutations. When administered alongside prednisone, it significantly enhances radiographic progression-free survival (rPFS) compared to conventional hormonal therapy alone.

Which Key Market Players Are Investing In Expansion And Innovation Within The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report

Which Regions Are Poised For Strategic Growth In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24495&type=smp

Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Urothelial Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model